Clinical Trial Update: Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase II trial evaluating nelfinavir with concurrent chemoradiotherapy in head and neck squamous cell carcinoma has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Nelfinavir (nelfinavir)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-07-25